Approaches and Devices Used in Pulmonary Drug Delivery System: A Review


Affiliations

  • SNJB's Shriman Suresh Dada Jain College of Pharmacy, Nasik, Maharastra, India
  • NANDHA College of Pharmacy, Erode, Tamil Nadu, India

Abstract

Targeting drug delivery into the lungs has become one of the most important aspects of systemic or local drug delivery. Consequently, in the last few years, techniques and new drug delivery devices intended to deliver drugs into the lungs have been widely developed. Currently, the main drug targeting regimens include direct application of a drug into the lungs, mostly by inhalation therapy using either pressurized metered dose inhalers (pMDI) or dry powder inhalers (DPI). Intratracheal administration is commonly used as a first approach in lung drug delivery in vivo. To convey a sufficient dose of drug to the lungs, suitable drug carriers are required. These can be solid, liquid, or gaseous excipients. Liposomes, nano and microparticles, cyclodextrins, microemulsions, micelles, suspensions, or solutions are all examples of this type of pharmaceutical carrier that have been successfully used to target drugs into lungs. The use of micro reservoir type systems offers clear advantages, such as high loading capacity and possibility of controlling size and permeability, and thus of controlling the release kinetics of the drugs from the carrier systems. These systems make it possible to use relatively small numbers of vector molecules to deliver substantial amounts of a drug to the target. This review discusses the approaches and devices required to be administer drug into the lungs.

Keywords

Targeting Drug Delivery, Drug Delivery Devices, Pressurized Metered Dose Inhalers, Liposomes, Microparticles.

Subject Discipline

Pharmacy and Pharmacology

Full Text:

References

Aulton’s Pharmaceutics, “The Design and Manufacture Of Medicinesâ€, Edited by Michael E. Aulton, 3rd edition, 540544,(2007).

Tortora G.J., Grabowski S. R., “Principles of Anatomy and Physiologyâ€, 10th edition, John willey & sons, Inc, 785-788.

Ross and Wilson, “Anatomy and Physiology in Health and Illness†By Waugh Anne and Grant Allison, 9th edition, Churchill Livingstone, Spain, 239-250.

Hofmann W., Mainelis G., Mohamed A., Balashazy I., Vaupotic J. and Kobal I., Comparison of Different Modeling Approaches in Current Lung Dosimetry Models, Environment International, Vol. 22, No. S1, 5965-5976,(1996).

Yu C.P. and Xu G.B., Predicted Deposition of Diesel Particles in Young Humans, J. Aerosol Sci., l8:4; 419-429 (1987).

Cohen B.S. and Asgharian B., Deposition of Ultrafine Particles in the Upper Airways: an Empirical Analysis, J. Aerosol Sci., Vol. 21,No. 6, 789-797,(1990)

Yu C. P., Exact Analysis of Aerosol Deposition during Steady Breathing, Powder Technology, 21: 55-62 (1978).

Berger C., Horvath H. and Schindler W., The Deposition of Soot Particles from Hot Gas Streams Through Pipes, J Sci., 26: 2; 211-217, (1995).

Finlay W. H., Wong J. P., Regional lung deposition of nebulized liposome-encapsulated ciprofloxacin .Int. J. Pharm, 167(1-2), 121-127, (1998).

Baseir M.M., Kellaway I.W., Poly (L-lactic acid) microspheres for pulmonary drug delivery :release kinetics and aerosolization studies. Int. J.Pharm. (1998): 135-145.

Courrier H.M., Butz N., Vandamme T.F., Pulmonary drug delivery systems: Recent developments and prospects. Critical Reviews In Therapeutic Drug Carrier Systems, 19 (4-5):425-498, (2002).

Freedman T. Medihaler therapy for bronchial asthma: a new type of aerosol therapy. Postgrad Med 1956; 20:667–673.

Dolovich M.B., Ahrens R.C., Hess D.R., Anderson P., Dhand R., Rau J.L., et al. Device selection and outcomes of aerosol therapy: evidence based guidelines. Chest;127(1):335–371, (2005).

Robertson C.F., Norden M.A., Fitzgerald D.A., Connor F.L., Van Asperen P.P., Cooper P.J., et al. Treatment of acute asthma: salbutamol via jet nebulizer vs spacer and metered dose inhaler. J Pediatric Child Health, 34(2):142–146,(1998).

Leversha A.M., Campanella S.G., Aickin R.P., Asher M.I. Costs and effectiveness of spacer versus nebulizer in young children with moderate and severe acute asthma. J Pediatric; 136(4): 497–502,(2000).

Dewar A.L., Stewart A., Cogswell J.J., Connett G.J. A randomised controlled trial to assess the relative benefits of large volume spacers and nebulisers to treat acute asthma in hospital. Arch Dis Child; 80(5):421–423,( 1999).

Gazarian M., Henry R.L., Wales S.R., Micallef B.E., Rood E.M., O’Meara M.W., Numa A.H. Evaluating the effectiveness of evidence-based guidelines for the use of spacer devices in children with acute asthma. Med J Aust 2001;174(8):394–397.

Cates C.J., Rowe B.H., Bara A. Holding chambers versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev 2000(2):(CD000052).

Dolovich M.B., Ahrens R.C., Hess D.R., Anderson P., Dhand R., Rau J.L., et al. Device selection and outcomes of aerosol therapy: evidence based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest;127(1): 335–371,(2005).

Atkins P.J., Crowder T.M. The design and development of inhalation drug delivery systems. In: Hickey A.

Pharmaceutical inhalation aerosol technology, 2nd ed. New York: Dekker; (2004).

Barry P.W., O’Callaghan C. The influence of inhaler selection on efficacy of asthma therapies. Adv Drug Delivery,55:7;879–923(2003).

Rau J.L. The inhalation of drugs: advantages and problems. Respiratory Care 2005;50(3):367–382.

O’Connor B.J. The ideal inhaler: design and characteristics to improve outcomes. Respiratory Med 2004;98 Suppl A:S10–S16.

Newman S.P., Clarke S.W. Bronchodilator delivery from Gentlehaler, a new low-velocity pressurized aerosol inhaler. Chest 1993;103(5):1442–1446.

Ganderton D. General factors influencing drug delivery to the lung. Respir Med 1997;91 Suppl A:13–16.

Newman S.P., Newhouse M.T. Effect of add-on devices for aerosol drug delivery: deposition studies and clinical aspects. J Aerosol Med 1996;9(1):55–70.

Giraud V., Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Respiratory J 2002;19(2): 246–251.

Borgstrom L., Derom E., Stahl E., Wahlin-Boll E., Pauwels R. The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am J Respir Crit Care Med 1996;153(5):1636–1640.

Ashurst I.I., Malton A, Prime D, Sumby B. Latest advances in the development of dry powder inhalers. Pharm Sci Techno, 2000;3(7): 246–256.

Norwood D.L., Prime D., Downey B.P., Creasey J., Sethi S.K., Haywood P. Analysis of polycyclic aromatic hydrocarbons in metered dose inhaler drug formulations by isotope dilution gas chromatography/ mass spectrometry. J Pharm Biomed Anal 1995;13(3):293–304.

Dalby R., Suman J. Inhalation therapy: technological milestones in asthma treatment. Adv Drug Deliv Rev; 55(7):779– 791,(2003).

Adjei A.L. & Gupta P. Therapeutic inhalation aerosols, In Inhalation delivery of therapeutic peptides and proteins, edited by A. L. Adjei and P. Gupta (Marcel Dekkar Inc, New York) 1997, 185.

Begat P., Morton D. A. V., Staniforth J. N. and Price R., “The cohesive adhesive balances in dry-powder inhaler formulations II: influence on fine particle delivery characteristicsâ€, Pharm Res 2004, Vol 21, No 10, pp 1826-1833.

Ashhurst I., Malton A., Prime D. and Sumby B., “Latest advances in the development of dry-powder inhalersâ€, PSTT 2000, Vol 3, No 7, pp 246-256.

Critical Reviews TM in Therapeutic Drug Carrier Systems 14(4): 395-453, 1997.

Pfutzner A., Mann A.E., Steiner S.S. TechnosphereTM/insulin – A new approach for effective delivery of human insulin via the pulmonary route. Diabetes Technol Ther 2002;4:589-94.

Cole J.L. and Hansen C.J., “Analytical ultra-centrifugation as a contemporary biomolecular research toolâ€. J Biomol Tech, Vol 10, pp 163-176,(1999).

Brange J., Whittingham J., Edwards D., Zhang Y.S., Wollmer A., Brandenburg D., Dodson G, and Finch J., “Insulin structure and diabetes treatmentâ€. Curr Sci, Vol 72, pp 470-476,(1997).

Brange J. and Volume A., “Insulin analogues with improved pharmacokinetic profilesâ€. Adv Drug Delivery Rev, Vol 35, pp 307-335,(1999).

Exubera package insert. FDA website. January 2006 (information available online at: access data.

fda.gov/scripts/cder/foi/label/2006/021868 lbl.pdf).

Cefalu WT, Skyler JS, Kourides IA, et al. Inhaled insulin Study Group. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med 2001;134:203-7.

Perera AD, Kapitza C, Nosek L, et al. Absorption and metabolic effect of inhaled insulin: Intrapatient variability after inhalation via the Aerodose® insulin inhaler in patients with type 2 diabetes. Diabetes Care 2002;25:2276-81.

Kim D, Mudaliar S, Chinnapongse S, et al. Dose-response relationships of inhaled insulin delivered via the Aerodose® insulin inhaler and subcutaneously injected insulin in patients with type 2 diabetes. Diabetes Care 2003;26:2842-7.

Rave K, Nosek L, Heinemann L, et al. Inhaled micronized crystalline human insulin using a dry powder inhaler. Doseresponse and time action profiles. Diabet Med 2004;21:763-8.

Schuster J, Rubsamen R, Lloyd P, et al. The AERx? aerosol delivery system. Pharm Res;14:35,4-7,(1997).

Farr S.J., McElduff A., Mather L.E., et al. Pulmonary insulin administration using the AERx? system: Physiological and physicochemical factors influencing insulin effectiveness in healthy fasting subjects. Diabetes Technol Ther 2000;2:185-97.

Azria M., “Treatment with calcitonin for osteoporosisâ€. Ann Rheum Dis, Vol 55, pp 700-714,(1996).

International Pharmaceutical Aerosol Consortium, 1997. Ensuring patient care- the role of the HFC MDI.

Metered dose pressurized aerosols and the ozone layer. European Resp. J. 3:495-497, (1990).


Refbacks

  • There are currently no refbacks.